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Transcriptional biomarkers of 
effective vaccination against 






















Foot and Mouth Disease (FMD)
• Highly contagious disease of mammals. Affects 
cattle, pigs, sheep, goats, etc. 
• Clinical signs can vary from mild to severe. 
Fatalities may occur, especially in young animals
• Spreads rapidly
• Seven serotypes of FMD virus (FMDV): no cross 
immunity between serotypes
• Severe economic losses
Outbreaks have major impact in 
countries economy
S. Levy Vaccine Technology III - 2010
FMDV vaccines
• Inactivated virus vaccines
• No cross-protection between serotypes 
• Multivalent vaccines to provide protection against 
the different serotypes
• Challenge tests are needed to establish a PD50 (50% 
protective dose) value or protection
• Challenge experiments requires appropriate 
biosecurity containment (Group 4 pathogens)
• Slow and expensive procedure 
O.I.E.- Manual of Diagnostic Tests and Vaccines for Terrestrial Animals
Potency Test
• PD50 test: The number of protective doses in a 
vaccine is estimated from the resistance to live 
virus challenge
• Cattle of at least 6 months of age, obtained from 
areas free from FMD should be used.
• Unprotected animals show lesions at sites other 
than the tongue
• Vaccines of high potency will prevent the 
development of local tongue lesions at the site of 
challenge
O.I.E.- Manual of Diagnostic Tests and Vaccines for Terrestrial Animals
FMDV vaccines
• The use of animals should be avoided where possible by 
the use of in vitro alternatives.
• A serological test is considered to be satisfactory where a 
valid correlation between the observed protection, and the 
specific antibody response has been established.
• Time consuming assay
O.I.E.- Manual of Diagnostic Tests and Vaccines for Terrestrial Animals
• Need to be delivered rapidly into the field for 
outbreaks attack
• Short shelf life
Cooperación Comunidad Europea - MERCOSUR
Cooperación Unión Europea - MERCOSUR




of protection as 
surrogate of protection
New technologies for development & control of 
Foot and Mouth vaccines
New vaccines
development
New analytical tools to
validate production
process
Functional genomics as a tool to 
define a molecular signature of 







Many parameters to be adjusted
• Time before processing (samples transport)
• Antigen preparation
• Time of stimulation (kinetics of the response)
• RNA conservation (QC for microarray) 
• Housekeeping gene 
• Initial qRT-PCR for sample selection
Genome-wide analysis of transcriptional 
responses
B. Taurus (Bovine) Oligo Microarray v2 Design ID 023647 4 x 44K
(Agilent Technologies)
1109 differentially expressed genes
344 genes upregulated




Main altered biological process
Immunological Disease
Cell-To-Cell Signaling and Interaction – Activation of Leukocytes
Cell-To-Cell Signaling and Interaction – Activation of Blood cells
Antigen Presentation – Activation of phagocytes
Antigen Presentation – Activation of antigen presenting cells
Vaccine Potency Test
• PD50 test: estimated from the resistance 
to live virus challenge
• Control animals must develop lesions on 
at least three feet
Unprotected animals show lesions at sites •
other than the tongue
• Vaccine of high potency will prevent the 
development of local tongue lesions at the 
site of challenge.
O.I.E.- Manual of Diagnostic Tests and Vaccines for Terrestrial Animals
341 differentially expressed genes
276 genes upregulated






A molecular signature of 
effective vaccination against 
FMDV?
qRT-PCR for microarray validation
• TLDA not suitable due to 
low numbers of inventored
genes
• Need to design appropriate set of 
primers
Gene Symbol Gene Name
Genes from 
microarray 
vaccinated vs naive 
animals
C5AR1 complement component 5a receptor 1
CCR1 chemokine (C-C motif) receptor 1
CD14 CD14 molecule
CD180 CD180 molecule
CD36 CD36 molecule (thrombospondin receptor)
CLEC7A C-type lectin domain family 7, member A
CSF1R colony stimulating factor 1 receptor
CXCL10 chemokine (C-X-C motif) ligand 10
CXCL5 chemokine (C-X-C motif) ligand 5
FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64)
FGF18 fibroblast growth factor 18
HCK hemopoietic cell kinase
IL12A interleukin 12A (p35)
IL12B interleukin 12B (p40)
IL2RA interleukin 2 receptor, alpha
LIF leukemia inhibitory factor (cholinergic differentiation factor)
MMP9 matrix metallopeptidase 9
PIGR polymeric immunoglobulin receptor
S100A9 S100 calcium binding protein A9
SLAMF1 signaling lymphocytic activation molecule family member 1
TAP1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
TG thyroglobulin
THBS1 thrombospondin 1
TNF tumor necrosis factor






BLA-DQB MHC class II antigen
BOLA-DQB major histocompatibility complex, class II, DQ beta
BoLA-DRB3 major histocompatibility complex, class II, DRB3
CCNB1 cyclin B1
CD3G CD3g molecule, gamma (CD3-TCR complex)
CDKN3 cyclin-dependent kinase inhibitor 3
EIF2B1 eukaryotic translation initiation factor 2B, subunit 1 alpha, 26kDa
EIF5A eukaryotic translation initiation factor 5A
GAPDH glyceraldehyde-3-phosphate dehydrogenase
GBP4 guanylate binding protein 4
IGJ immunoglobulin J polypeptide, linker protein for Ig α and µ polypeptides
IRF8 interferon regulatory factor 8
KIR3DL2 killer cell immunoglobulin-like receptor
RPL10 ribosomal protein L10
RPS24 ribosomal protein S24
THSD4 thrombospondin, type I, domain containing 4
Gene Symbol Gene Name
Genes present in both 
microarrays
CLEC1A C-type lectin domain family 1, member A
CCL4 chemokine (C-C motif) ligand 4
CREB3 cAMP responsive element binding protein 3
CXCR2 chemokine (C-X-C motif) receptor 2
CXCR5 chemokine (C-X-C motif) receptor 5
DNAJA1 DnaJ (Hsp40) homolog, subfamily A, member 1
FTSJ2 FtsJ homolog 2 (E. coli)
GADD45B growth arrest and DNA-damage-inducible, beta
GPR128 G protein-coupled receptor 128
GPR137B G protein-coupled receptor 137B
IFN-γ interferon, gamma
IGF2 insulin-like growth factor 2 (somatomedin A)
IL23R interleukin 23 receptor
P2RY6 pyrimidinergic receptor P2Y, G-protein coupled, 6
RPL9 ribosomal protein L9
SIX5 SIX homeobox 5






































































IFN-γ a suitable 
biomarker of 
Symptomatic
vaccination & high 
protection ?
Better than Neutralizing antibodies ?
Symptomatic
Molecular signature seems to better 
differentiate between highly protected and 
symptomatic animals
Animal Symptoms Neutralizing antibodies (UA) Increase IFN-γ mRNA
1 - 3,48 0,01034
2 - 2,26 0,01624
4 - 3,55 0,01155
11 - 2,99 0,00478
5 - 2,35 0,00463
10 - 3,29 0,00271
7 + 3,48 0,00123
8 + 2,26 0,00154
9 + 3,55 0,00177
13 + 2,99 0,00015
3 + 2,17 0,00728
12 + 1,79 0,00082
Naïve 1 + 0,00086
NaÏve 2 + 0,00058
Conclusions & future directions
• There is a need for proper subrogates of protection in 
vaccines
• This is especially important when trying to translate 
research from preclinical studies to clinical trials
• Genome-wide transcriptional profiling allowed the 
discovery of biomarkers that seem more accurate 
than neutralizing antibodies for FMD
• Need to conduct large screenings to validate the 
process
• This shall accelerate the release of new batches of 































Largest beef consumers in the 
world: 53 kg per capita
The biggest “asado”: Guinnes record 2008
Beaches of Uruguay
Beaches of Uruguay
World cup South Africa 2010
American Cup Argentina 2011

